BioSpace News Archive

Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA).

Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is proud to announce it has signed a Letter of Intent entering into a partnership with Irwin Naturals Inc. (“Irwin”) (CSE: IWIN) (OTC: IWINF) (FRA: 97X) to launch Clinical Research Services across Irwin’s growing U.S. based network of clinics, Emergence

Valbiotis, a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its roadmap for 2023.

KRONOS ADVANCED TECHNOLOGIES, INC. announced today that the U.S. Food and Drug Administration (FDA) has recently granted 510(k) clearance, classifying it as a Class II Medical Device.

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE (FSE: EVT; NASDAQ: EVO).

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn’s placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community.

Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.

Emergent Health Corp. announced today that it intends to retain an independent certified public accountant to audit Emergents financial statements in accordance with Securities and Exchange Commission Generally Accepted Accounting Principles and an experienced Securities Attorney to prepare and file either Form 10 or Form S-1 Registration Statement with the SEC to become a fully reporting SEC Company subject to the filing requirements of Section 15(d) of the Securities Exchange Act of 1934.

Fluidx Medical Technology, Inc., released information regarding the success of the IMPASS Embolic Device in in-vivo research related to middle meningeal artery embolizations which can be used to treat chronic subdural hematomas on the surface of the brain.

Complete Genomics Inc today unveiled its full sequencing platforms at Biotech Showcase during JP Morgan Healthcare Conference Week 2023.